About Celgene
Celgene is a Healthcare company based in Summit (United States) founded in 1986, and was acquired by Bristol-Myers Squibb in January 2019. Therapies for cancer and inflammatory diseases are developed. Celgene has raised $45 million across 8 funding rounds from investors including Mesoblast, Bristol-Myers Squibb and Geneva Partners. The company has 4,891 employees. Celgene has completed 11 acquisitions, including Abraxis BioScience, Acetylon and Avila Therapeutics. Its chief executive, as recorded, is Sol J. Bare. Its focus areas include Diversified Pharmaceuticals, Biopharma Outsourcing, CRO and Clinical Development. Its competitors include Poseida Therapeutics, Juno Therapeutics and TScan Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Celgene is developing therapies for multiple myeloma, inflammatory diseases, and various forms of cancer. The companys lead molecule BCMA CAR T is used for treating multiple myeloma. The candidate is in phase II clinical study. Other candidates are in phase I and II, used for treating various cancers. In 2018, the company recorded annual revenues of 15.28B, and a net profit of 4.04B.
- Headquarters Summit, United States
- Employees 4,891
- Stage Acquired
- SectorsHealthcare
- Website celgene.com
- Social LinkedIn Facebook
- Acquired by Bristol-Myers Squibb (Jan 2019)
- Legal Name Celgene
- Total Equity Funding$45M (USD)
in 8 rounds
- Latest Funding Round$4.1M (USD), Post-IPO
Feb 2018
- InvestorsMesoblast
& 3 more
- Employee Count4,891
- Investments & AcquisitionsAbraxis BioScience
& 10 more
- Acquired byBristol-Myers Squibb
(Jan 2019)
Funding Insights of Celgene
Celgene has successfully raised a total of $45M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.1 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $45M
- Total Rounds 8
- Last Round Post-IPO — $4.1M
- First Round $3.23M
(Oct 2008)
- Investors Count 3
All 8 funding rounds of Celgene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2018 | $4.1M | Post-IPO | – | – | |
| Nov 2017 | $3B | Debt – Conventional | – | – | – |
| Apr 2015 | $45M | Private Equity Round | – | – | |
| Mar 2013 | $7.49M | Grant | – | – | |
| Oct 2012 | $7.49M | Grant | – | – | |
| Sep 2010 | $3.23M | Grant | – | – | |
| Mar 2010 | $10.06M | Grant | – | – | |
| Oct 2008 | $3.23M | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Celgene
Celgene has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Mesoblast, Bristol-Myers Squibb and Geneva Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Offers comprehensive investment advisory and financial planning services to clients. | 2004 | genevapartnersllc.com | Lake Geneva, United States | |
Biotherapeutics derived from proprietary adult stem cell-based technologies | 2004 | mesoblast.com | Melbourne, Australia | |
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States | ||
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States |
Investor details for Celgene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Celgene
1418 people are tracked at Celgene (871 in leadership, 11 in board & advisors, 536 in team); the tracked headcount is 4,891.
| Name | Role | Group |
|---|---|---|
Sol J. Bare | Chairman & CEO | Leadership |
Lakshmikant Bajpai | Director And Head Of Analytical Research & Development | Leadership |
Tughan Demirbilek | Head Of Strategy & Operations Intercontinental Region | Leadership |
Elaina Gillule | Human Resources Business Partner- R&d - Global Development Operations | Leadership |
Mark L Clarke | Associate Director Cell Therapy Development | Leadership |
Frank Marra | Vice President, Worldwide Commercialization Operations | Leadership |
Alex Turoczi | Director, End To End AI Marketing Integration Lead, Worldwide Commercialization Excellence | Leadership |
Yolanda Caringal | Senior Director | Leadership |
Nitin Bindal | Business Unit Director - Oncology And Hematology | Leadership |
Stephane Strebelle | Executive Director Finance, US Commercialization Fp&a | Leadership |
Tyler Longmire | Director | Leadership |
Lisa Evans | Director, Omnichannel Strategy, Neuroscience | Leadership |
Federico L. | Senior Director, Value Chain Analytics | Leadership |
Kevan J. Evans II | Director | Global Business Performance, Strategy & Excellence; People Organization | Leadership |
Shayla O. | Associate Director, People Services Communications | People & Culture Internal Comms | Leadership |
Kami Wagner | Director, R&d Quality- Clinical Auditing | Leadership |
Kald A. | Head Of Worldwide Medical - Oncology | Leadership |
Joanna Wolkowski | Head Of Global Pricing, Health Systems Analytics, And Reimbursement Operations | Leadership |
Imara Charles | Vice President, Chief Of Staff, Global Product Development And Supply | Leadership |
Christian Lamont | Executive Director, Automated Product Market Compliance | Leadership |
1398 more people are available in the full profile.
Complete people profiles for Celgene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Celgene
Celgene has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include Abraxis BioScience, Acetylon and Avila Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | junotherapeutics.com | Seattle, United States | 2013 | Jan 2018 | $9B | |
Regulatory T cell therapeutics for autoimmune diseases are developed. | deliniabio.com | Cambridge, United States | 2015 | Jan 2017 | $300M | |
Next-generation selective HDAC inhibitors are developed for multiple diseases. | acetylon.com | Boston, United States | 2008 | Dec 2016 | •••• | |
T-cell bispecific antibodies are developed for cancer treatment. | engmab.com | Schwyz, Switzerland | 2013 | Oct 2016 | $600M | |
Biopharmaceutical products for serious diseases are discovered and developed. | quanticel.com | San Diego, United States | 2010 | Apr 2015 | $485M | |
Small molecule TLR8 agonists are developed for cancer immunotherapy. | ventirx.com | Seattle, United States | 2006 | Oct 2012 | $35M | |
Targeted covalent drugs are developed for cancer and autoimmune diseases. | avilatx.com | Waltham, United States | 2006 | Jan 2012 | $350M | |
Protein-based nanoparticle chemotherapeutics for cancer are developed. | abraxisbio.com | Chicago, United States | 2005 | Jun 2010 | $2.9B | |
Drugs for cancer treatment are developed by the company. | gloucesterpharma.com | Cambridge, United States | 2002 | Dec 2009 | $340M | |
Therapies for the treatment of hematology and oncology disorders | pharmion.com | Boulder, United States | 2000 | Nov 2007 | $2.9B |
Complete acquisition details for Celgene
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Celgene
15 dated milestones of Celgene across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Celgene is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Pharmion.
- Funding First funding round of $3.2M.
- Acquisition Acquires Gloucester Pharmaceuticals.
- Acquisition Acquires Abraxis BioScience.
- Acquisition Acquires Avila Therapeutics.
- Acquisition Acquires VentiRx.
- Acquisition Acquires Quanticel.
- Acquisition Acquires EngMab.
- Acquisition Acquires Acetylon.
- Acquisition Acquires Delinia.
- Acquisition Acquires Juno Therapeutics.
- Funding Latest funding round, Post-IPO, of $4.1M.
- Exit Acquired by Bristol-Myers Squibb.
Competitors of Celgene
Celgene has 3 listed competitors in our database, 3 of them funded. They include Poseida Therapeutics, Juno Therapeutics and TScan Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. |
Detailed competitors of Celgene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Celgene
Websites that share an audience with Celgene (celgene.com).
Websites whose visitors overlap most with Celgene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ariad.com | 100% | View details | |||
emdserono.com | emdserono.com | 84% | #1,249,632 | – | |
| lifecell.com | 72% | View details | |||
| gilead.com | 61% | 576.5K | #103,109 | View details | |
ehcca.com | ehcca.com | 57% | #4,154,277 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Celgene
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as Celgene (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Celgene
Complete news archive for Celgene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celgene
Celgene was founded in 1986 and raised its 1st funding round 22 years after it was founded.
Celgene is headquartered in Summit, United States.
Sol J. Bare is the CEO of Celgene, as recorded in our data.
Celgene is a funded company, having raised a total of $45M across 8 funding rounds to date. The company's 1st funding round was a Grant of $3.23M, raised on Oct 2008.
Celgene has 4,891 employees.
Celgene is developing therapies for multiple myeloma, inflammatory diseases, and various forms of cancer. The companys lead molecule BCMA CAR T is used for treating multiple myeloma. The candidate is in phase II clinical study. Other candidates are in phase I and II, used for treating various cancers. In 2018, the company recorded annual revenues of 15.28B, and a net profit of 4.04B.
Celgene's top competitors include Juno Therapeutics, Poseida Therapeutics and TScan Therapeutics.
Celgene has made 11 acquisitions, including Abraxis BioScience, Acetylon, and Avila Therapeutics.
Celgene has 4 investors. Key investors include Mesoblast, Bristol-Myers Squibb, Geneva Partners, and Military Health.
Celgene operates through Celgene.
Yes. Celgene was acquired by Bristol-Myers Squibb in January 2019.